Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Retained Earnings (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Retained Earnings data on record, last reported at -$632.5 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 13.31% year-over-year to -$632.5 million; the TTM value through Dec 2025 reached -$632.5 million, down 13.31%, while the annual FY2025 figure was -$632.5 million, 13.31% down from the prior year.
  • Retained Earnings reached -$632.5 million in Q4 2025 per FHTX's latest filing, down from -$610.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $14000.0 in Q1 2025 and bottomed at -$632.5 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$304.0 million, with a median of -$304.8 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 39760.0% in 2022, then skyrocketed 100.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$10000.0 in 2021, then tumbled by 39760.0% to -$4.0 million in 2022, then crashed by 11730.51% to -$471.6 million in 2023, then dropped by 18.37% to -$558.2 million in 2024, then decreased by 13.31% to -$632.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$632.5 million in Q4 2025, -$610.8 million in Q3 2025, and -$595.0 million in Q2 2025.